Our compagny

Ambitious molecules deserve powerful assays

Our mission is to help develop safe and efficient molecules of benefit to patients. We track and analyse if and how compounds affect mitochondrial functionality and integrity.Our services are designed for scientists across the board, from the pharmaceutical, biotech, cosmetic, chemistry and agrochemistry sectors, to academia.

Mitologics SAS – created in 2009 – is based in the Paris region. The founding team consists of two women scientists – Dr Annie Borgne-Sanchez and Dr Nelly Buron – and Mathieu Porceddu. We consider it a shared vision stemming from our combined experience in academic research, the pharmaceutical industry and biotechnology company.

Using our scientific and technical backgrounds in cellular and molecular biology, we have developed and validated affordable in vitro and ex vivo mitochondrial assays to assess the toxicology and efficacy of test compounds. Today, our approach has been honed through experience gathered over the years working with more than one hundred clients based mainly in Europe, the USA, and Asia.

To provide our customers with the best possible results, we strive for reliable operation, always on the lookout for the optimal experimental setting to meet clients’ needs.

Management team

Dr. Annie Borgne-Sanchez

Co-founder, President, CEO-CSO
Annie was part of the team that co-founded Mitologics in 2009. Her role involves taking responsibility for managing and developing both service and R&D activities. She is listed as co-author on 30 peer-reviewed publications and 5 international patents. Annie’s career has been rich and varied. She was awarded her PhD in 1998 for a project undertaken in Laurent Meijer’s laboratory (CNRS, Roscoff) related to cell cycle regulation and CDK inhibitors. In 2001, she was a postdoctoral research fellow at Cancer Research UK (London) – working on cell cycle checkpoints in yeast in Paul Nurse's laboratory when he was awarded the Nobel Prize. Subsequently, she joined the Servier Research Institute where she worked on new anti-cancer targets in cell cycle/apoptosis models in their Oncology department. Toward the end of 2002, Annie joined Theraptosis SA, then located at the Pasteur Institute (Paris). From 2005 to 2008, she was responsible for managing the department housing the Cancer drug discovery-Mitochondria screening platform.

Dr. Nelly Buron

Co-founder, Head of R&D, Study manager
Nelly is one of Mitologics’ co-founders, she oversees our internal R&D activities and manages contract research studies. She is listed as co-author on 18 peer-reviewed publications, drawn from her rich career in biological research spanning 20 years. During this time, Nelly mostly specialized in cell death mechanisms. She started on this path with her PhD – obtained in 2006 in Pr. Eric Solary’s laboratory (INSERM U866, Cell Death and Cancer). She then embarked on her industrial career at Theraptosis SA, where she worked on anti-tumour drug candidates and characterized their mechanisms of action.

Mathieu Porceddu

Co-founder, Platform manager
Mathieu was part of Mitologics’ founding team in 2009. He has been our expert in isolation of all types of mitochondria for over 15 years. He is also responsible for the technological platforms. He is a co-author on 11 peer-reviewed publications. Mathieu joined the Cancer drug discovery department at Theraptosis SA immediately after his degree in Biology, obtained at Paris-Orsay University in 2006. His specializations are Molecular and Cellular Biology.

Dr. Cécile Martel

Senior Research Scientist, Study manager
Cécile joined Mitologics in 2017 to handle our collaborative academic research programs. She now undertakes the further development of innovative efficacy testing and manages contract research studies. She is a co-author on 26 peer-reviewed publications. Cécile was awarded her PhD in 2011 by the University Paris Sud for research focusing on the implication of mitochondria in hepatic steatosis. From 2012 to 2016, she was a postdoctoral fellow at the Montreal Heart Institute (Institut de cardiologie de Montréal), where she worked on the role played by Angiopoietin-like 2 in stress-induced cardiac physiopathology.

Claire Pertuiset

Senior Associate Research Scientist
Claire joined Mitologics in 2014 to develop new experimental protocols elucidating compounds’ mechanisms of action and perform contract research studies. She is named as a co-author on 7 peer-reviewed publications. Claire graduated with a Master’s degree from the University Paris Sud in 2005. The focus of her degree was quality control for pharmaceuticals. She subsequently worked in academic research, investigating mitochondrial physiophatology (INSERM) and in 2012 she joined Quality Assistance SA (Belgium) to develop analytical methods in GMP conditions. This combined experience makes her a specialist in Molecular and Cellular Biology with a strong focus on Quality Assurance.

Léa Zennaro

Associate Research Scientist
Léa joined Mitologics in 2021 to further develop processes for molecular screening and perform contract research studies in GMP-environment compliance. She is a co-author on 3 peer-reviewed publications. Léa is a graduate of engineering from University of Technology of Compiègne (UTC). She started her career in 2019 as a molecular and cellular biologist. After training in the Cardiovascular and Metabolism department at Sanofi, she worked for Sénart Fontainebleau University Institute of Technology (IUT) and Inovarion, completing missions at the Centre de Recherche des Cordeliers and the Imagine Institute (Paris).


An international player in the mitochondria field since 2009

IMI-Respiratory NTM project– Progress novel assets for non-tubercular mycobacteria (NTM) causing lung diseases – awarded funding from the European Union and Johnson & Johnson. The project coordinated by Dr Meidert H. Lamers (Leiden University, Netherlands) is run in collaboration with Janssen Pharmaceutica NV (Belgium).


IMI-Respiratory TB project– New treatments for Tuberculosis (TB) – awarded funding from the European Union and Johnson & Johnson. The project coordinated by Dr Meidert H. Lamers (Leiden University, Netherlands) is run in collaboration with Janssen Pharmaceutica NV (Belgium).


IACANT project – New compounds targeting mitochondria in cancer cells – gained support from the Paris-Région – as part of its Investissement d’Avenir PIA3 programme. The project was steered by Mitologics.

June 2019

In June Mitologics established its laboratory at the Faculté de Santé de Créteil (France)


Mitologics joined the Cosmetic Valley competitiveness cluster


In January, Mitologics listed as a supplier on Scientist.com, the world's largest marketplace for research services.


The MITOXDRUGS project, to study and predict drug-induced steatosis, awarded funding by the French national research agency (ANR-CE) as part of their “Vie Santé et Bien-être” call. Dr. Bernard Fromenty (Inserm U1241, Université de Rennes 1) was PI for this project.


Mitologics established a partnership with Toxys (Leiden, Pays-Bas) to combine MiToxView® and Tox Tracker® platforms to better predict the risks of compound toxicity.

Find out more > Press release, March 2016


Mitologics contributed to the CARMMA programme – CARdiac and skeletal Muscle alteration in relation to Metabolic diseases and Ageing: role of Adipose Tissue – supported by Hospital-University Research in the health sciences (RHU en santé) through its Investissement d’Avenir programme. The project PI was Prof. Geneviève Derumeaux (Hôpital Henry Mondor, Créteil).


Mitologics became a member of AFSSI, the French association of R&D service providers contributing to innovative research programmes in Life Sciences.


Award to Mitologics from the French Ministry of Education and Research during its National competition for assistance with the creation of innovative technology companies (Concours national d’aide à la création d’entreprises de technologies innovantes) in the Création & Développement category.


Mitologics established its headquarters at Biocitech (Romainville, France)


Mitologics partnered with Biopredic International (Rennes, France) to propose HepaRG cells and HepaRG mitochondria as predictive models for drug-induced liver injury (DILI) caused by mitochondrial damage.


Mitologics reaches a Crédit-Impôt-Recherche (CIR) agreement for R&D contract services.


Mitologics recognized in the competition for new talent (Concours des talents) run by the Paris Region.


Mitologics joined the MEDICEN Paris-Région competitiveness cluster


Mitologics contributed to the PHARMECO project on hepatotoxicity of contaminants in medicines. The project was funded by the French national research agency (ANR-CES), in the “Contaminants, Ecosystems, Health” category; PI Dr. Bernard Fromenty (INSERM U1241, Université de Rennes 1).


Mitologics established a partnership with Horizon Discovery Ltd (Cambridge, UK), including a joint marketing agreement for the use of X-ManTM cell lines, bearing mutations in P53, Ras and PI3K.


Mitologics contributed to the URAAPO project on ADP/ATP translocator, awarded funding from the French national research agency (ANR-PCV); PI Dr. Catherine Brenner (Inserm U769, Châtenay-Malabry).


Mitologics established its laboratory at Robert Debré Hospital (Paris, France).


Award to Mitologics from the French Ministry of Education and Research at the National competition for assistance with the creation of innovative technology companies (Concours national d’aide à la création d’entreprises de technologies innovantes) in the Emergence


Mitologics SAS created in February.


Incubation at Agoranov.

Why focus on mitochondria?

Mitochondria: an essential organelle and a valuable therapeutic target

Mitochondria control the balance between life and death in eukaryotic cells, playing a key role in drug development. As they may be harmed by many compounds, examining mitochondrial function is an important checkpoint for compound safety.
In addition, this organelle constitutes a target of choice to develop innovative medicines for a variety of diseases, or anti-ageing compounds aiming to prevent age-related damage. Mitologics’ offer meets these two needs, by providing services to test both toxicity and efficacy.

Mitochondria form a highly dynamic network of specialized compartments: the outer membrane, the intermembrane space, the inner membrane and its cristae, and the matrix containing the mtDNA. These sites work together to create the optimal conditions for metabolic reactions.

As the cell’s energy factory, mitochondria play a major role in ATP production by the respiratory chain, with the main enzymes located in and around the inner membrane. The OxPHOS machinery catalyses a chain reaction transforming oxygen and substrates coming from fuel molecules (glucose, glycogen, fatty acids, etc.) into CO2 and H2O, producing ATP. Mitochondria are thus an essential organelle in all eukaryotic cells.

The mitochondrion contributes significantly to cellular oxidative stress, as a result of electron leaks from the respiratory chain – mainly at complex I and complex III – leading to the production of reactive oxygen species (ROS).  The mitochondrion is itself a target of ROS, with effects including irreversible damage to mtDNA, mitochondrial membrane lipids, and mitochondrial proteins, resulting in mitochondrial dysfunction, and potentially creating a vicious cycle. To protect itself, the mitochondrion contains an efficient antioxidant system associated with repair system maintaining ROS at low level under non-pathological conditions. 

In addition to its role in energy metabolism, one of the mitochondrion’s key roles is to control cell death. Death-regulating proteins located in the outer membrane, make the membrane permeable when triggered by death stimuli. As a result, pro-apoptotic molecules are released from the mitochondria, leading to a cascade of death signals.

Finally, mitochondrial dynamics is part of the cell’s quality control system, guaranteeing a continual pool of functional mitochondria. The processes involved include mitochondrial biogenesis, fusion and fission, to maintain mitochondrial function, as well as mitophagy to eliminate damaged mitochondria.

Working with us: how, when, why

Bespoke services to boost industrial and academic sectors’ projects, from compound discovery to commercialization, compliant with the 3R principle

Since 2009, we have used our expertise and know-how in the field of mitochondria to design and propose studies meeting our clients’ needs.

Mitologics operates for the biotech/pharmaceutical, cosmetic, chemistry and agrochemistry sectors as well as academic laboratories. Following discussions with clients’ CSO, R&D director, project manager, head of project, or scientists, we can provide:

  • Fee-for-service R&D studies,
  • Consulting services,
  • Collaborative public-private projects.

Mitologics intervenes at different stages of clients’ projects:

Potential mitotoxicity can be verified at each stage of drug discovery, in high- or medium-throughput assays. Compounds that present signs of organ toxicity in preclinical in vivo models should be tested on our MiToxView® platform. Results can help determine if and how mitochondrial dysfunction causes organ toxicity, allowing you to adapt the drug development strategy.

Mitologics offers two other platforms: MitoPathway® and MitoXpert®. Derived from relevant in vitro models, results can demonstrate efficacy and allow exploration of the mechanism of action (MoA) of compounds and/or the involvement of mitochondria in particular diseases.

Mitologics can investigate the impact of a given compound on mitochondrial function/content and cell death pathways in human blood samples (PBMCs) or biopsies collected during clinical trials. These tests are run on our MiToxView® and MitoXpert® platforms.

Customized bio-assays can be set up and validated by Mitologics during drug development. These assays can then be routinely used in a GMP-compliant environment for the release of commercial batches.

Our tests represent an alternative to animal testing, helping to make your studies compliant with the 3R principles.

Replacement, reduction, refinement: Mitologics’ approach can be a fully operational alternative to animal testing.

Investigations are undertaken using cultured human cells or mitochondria isolated from human cell lines, as part of the Replacement principle.

Ex vivo assays on mitochondria purified from rodent organs allow numerous compounds to be tested at a range of doses. This process allows a 40-fold reduction in the number of rodents required for preclinical studies. MiToxView® thus allows you to integrate Reduction in your practice, without risking the quality of your results.

Finally, MiToxView® can robustly identify mitotoxic compounds at an early stage, thus reducing the number of in vivo studies required, or helping to guide further development, meeting both the Reduction and Refinement criteria.

All discussions and exchanges with customers or partners are confidential whether an NDA is signed or not. The intellectual property in relation to any projects or products we receive is strictly respected, as mentioned in our contracts.

The experimental phase starts as soon as the study proposal has been signed, and the compounds or biological materials have arrived at our lab facilities at the Faculté de Santé de Créteil (France).


Careers at Mitologics

Mitologics is open for applications from talented and skilled collaborators.

If you are interested in joining our team, please contact us.